Spinal Manipulation and Patient Self-Management for Preventing Acute to Chronic Back Pain

NCT03581123 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1000

Last updated 2025-10-16

Study results available
· View outcomes & findings →

Summary

This is a study of adults with acute low back pain flare-up at risk of becoming chronic and disabling. The study tests how well spinal manipulation and guided selfcare work compared to standard medical care. The treatments last up to eight weeks and participants will be followed for one year.

Conditions

  • Acute Pain
  • Low Back Pain, Mechanical

Interventions

BEHAVIORAL

Supported-Self Management (SSM)

Provides low back pain sufferers opportunities to develop the capacity and motivation to self-manage their pain in an adaptive manner. This includes psychological/behavioral strategies, mind-body approaches, lifestyle advice, pain education and pain coping.

OTHER

Spinal Manipulation Therapy (SMT)

SMT will address the biological and physical aspects of low back pain (e.g. spinal dysfunction) with the intention of restoring maximum movement and functional ability of the spine.

COMBINATION_PRODUCT

SMT + SSM

Combination Treatment

DRUG

Standard Medical Care (SMC)

Guideline based medical care informed by the American College of Physicians' guidelines on noninvasive treatment for low back pain.

Sponsors & Collaborators

Principal Investigators

  • Gert Bronfort, PhD, DC · University of Minnesota

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-01
Primary Completion
2024-06-12
Completion
2024-06-12
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03581123 on ClinicalTrials.gov